Ranbaxy, a subsidiary of the Japanese Daiichi Sankyo Group, is India's largest pharmaceutical company, producing a wide range of quality, affordable generic medicines for sale both in India and internationally.

Following the April 2009 launch of Olvance (olmesartan medoxomil), an antihypertensive, originally discovered by Daiichi Sankyo, Prasita is the second product from the Daiichi Sankyo portfolio to be introduced in India through the strong Ranbaxy business network. Ranbaxy intends to create awareness, understanding and acceptance of the new antiplatelet therapy among the target audiences in the country.

Mr Takashi Shoda, President & CEO of Daiichi Sankyo, said “the launch of our two top flagship products, olmesartan medoxomil and prasugrel, by Ranbaxy shows our serious commitment to India”.

India is one of the world’s most attractive and rapidly growing markets, generating nearly US$8 billion in pharmaceutical sales this year, and expected to more than double by 2015.

Pharmaceutical sales in emerging markets, like India’s, are expected to grow at three times the rate of developed markets and to account for 70% of pharmaceutical growth over the next years. This explosive growth is a result of demographics, rising incomes, modernisation of healthcare systems and an increase in the treatment of chronic disease, all of which create greater demand for medicines.

Reference:

Ranbaxy Latest News, Ranbaxy launches antiplatelet agent Prasugrel in India, June 10, 2010